Eisai/Biogen’s Lecanemab: Pricing Pressure Builds Ahead Of Likely US Approval Of Alzheimer’s Drug
Executive Summary
After the commercial and public relations debacle driven by Biogen’s original pricing for the companies’ predecessor drug for Alzheimer’s, Aduhelm, Eisai is feeling the heat to ensure the US price for lecanemab is in line with stakeholder expectations.
You may also be interested in...
Eisai Pricing For Lecanemab Reflects Concern With Medicare ‘Sustainability,’ ‘Giving Back,’ Firm Says
Despite internal modeling indicating lecanemab offers a ‘societal value’ of around $37,600 per year, the company has decided on a list price of around $26,500 annually to moderate the impact on Medicare and patients.
US FDA Neurology Drugs Program Gains Boost In FY 2023 Funding Bill Amid Calls To Clarify Development Policies
US FDA gains a nearly 7% increase in non-user fee funding, some of which will go for neurology drug guidance.
Eisai Plots A Meticulous Path To Medicare Coverage For Lecanemab
Ivan Cheung, Eisai’s US CEO, explains the ‘question-by-question’ the company is taking to convince the Centers for Medicare and Medicaid Services that its Phase III Clarity AD results in Alzheimer’s offer the ‘high level of evidence’ needed for smooth reimbursement of lecanemab.